Killer-cell immunoglobulin-like receptors associate with HIV-1 infection in a narrow-source Han Chinese cohort

Linghang Wang\textsuperscript{1,2,3}, Yonghong Zhang\textsuperscript{3,4}, Keyi Xu\textsuperscript{1}, Tao Dong\textsuperscript{2,3}, Sarah Rowland-Jones\textsuperscript{2}, Louis-Marie Yindom\textsuperscript{2,*}

\textsuperscript{1} Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China, \textsuperscript{2} Nuffield Department of Medicine, Headington, Oxford, United Kingdom, \textsuperscript{3} MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom, \textsuperscript{4} Beijing You An Hospital, Capital Medical University, Beijing, People’s Republic of China

* louis-marie.yindom@ndm.ox.ac.uk

Abstract

Background

The HIV pandemic remains the most serious challenge to public health worldwide. The hallmark characteristics of the disease is the eventual failure of the immune system to control opportunistic infections and death. However not everyone who has HIV develops the disease at the same rate and so we are studying how the immune system works to control the virus in those who have been infected for decades and remain relatively healthy without the need of anti-retroviral therapy (ART).

Methods

Genomic DNA samples from 513 Chinese Han individuals from Henan province were typed for 15 KIR and 3 HLA class I genes. Genotype frequencies were compared between a village cohort of 261 former plasma donors (SM cohort) infected with HIV-1 through an illegal plasma donor scheme who survived more than 10 years of infection without ART and 252 ethnically-matched healthy controls from a nearby village. KIR and HLA were molecularly typed using a combination of polymerase chain reaction (PCR) with sequence-specific primers (PCR-SSP) and sequence based techniques.

Results

All 15 KIR genes were observed in the study population at various frequencies. \textit{KIR2DL3} was significantly less common in the HIV-1 infected group (95.8\% vs 99.2\%, \textit{p} = 0.021). The combination of \textit{KIR3DS1} with homozygosity for HLA-Bw4 alleles (the putative ligand for \textit{KIR3DS1}) was significantly less frequent in the HIV-1 infected group than in the control group (6.0\% vs 12.0\% respectively, \textit{p} = 0.023).

Conclusion

Specific KIR-HLA compound genotypes associate with differential outcomes to infection and disease progression following exposure to a narrow-source HIV-1.
Introduction

Natural Killer (NK) cells play a bridging role between innate immunity and adaptive immunity to control viral infection and malignant diseases. NK cells can be rapidly activated in the absence of previous antigen sensitisation and therefore represent a crucial first line of defence against viral infections [1]. Whether or not a NK cell is activated is determined by the balance of an array of activating signals and inhibitory signals transduced from their cell-surface receptors. Of all the NK cell receptors, KIRs are by far the most polymorphic and could therefore explain differential responses to viral infections between individuals.

The KIR gene family is encoded within a 100–200 Kb region of the Leukocyte Receptor Complex (LRC) located on human chromosome 19, and consists of 15 functional gene loci and 2 pseudogenes [2]. The extensive diversity within the KIR system is found at several levels: locus, allele, ligands and within their expression patterns. The expression of KIRs on NK cells is stochastic and variegated [3,4]. Potentially all these levels of KIR variation can influence the host immune responses to infection.

KIR molecules are classified according to the number of extra-cellular domains, as either KIR2D or KIR3D molecules. KIR molecules are also divided into L or S, representing long or short cytoplasmic tails, respectively. Broadly speaking, KIR2DL and KIR3DL genes encode inhibitory molecules (with the exception of KIR2DL4 which has both inhibitory and activation potential), whereas KIR2DS and KIR3DS encode activating receptors. At the haplotype level, KIR genes segregate in a unique manner into two distinctive groups namely A and B that are maintained in different world populations by balancing selection [5,6]. Haplotype A is relatively simple with nine genes encoding predominantly inhibitory receptors, with only one activating gene (KIR2DS4) if expressed. Conversely the B haplotypes constitute a more extensive grouping that contain a mixture of activating and inhibitory KIRs. Present in each haplotype are four framework genes (KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2) that delimit three framework regions namely: the centromeric part from KIR3DL3 to KIR3DP1, the central region from KIR3DP1 to KIR2DL4, and the telomeric part from KIR2DL4 to KIR3DL2 [7,8]. The central part is the recombination hotspot while both the centromeric and telomeric regions have variable gene-content. KIR molecules regulate the activity of NK and some T cells through interaction with specific Human Leucocyte Antigen (HLA) class I molecules which are their principal ligands. A functional interaction can only occur when both ligands and receptors are co-expressed in the same individual.

Several reports have described associations between particular KIR-HLA combinations and clinical outcome in HIV infections [9–15]. A compound genotype comprising KIR3DS1 and Bw4-80I (isoleucine at position 80 of the corresponding HLA-B alleles) was shown to have a protective effect against AIDS progression in ART naive HIV-1 infected individuals [13]. This compound genotype was further shown to correlate with lower viral load and protection from opportunistic infections [14]. However the protective effect of this compound genotype was not seen in two other studies [11,16]. Recent evidences suggest that KIR3DS1 binds to HLA-F [17,18] but no direct binding to HLA-B Bw4-80I has so far been demonstrated [19,20]. Nevertheless, a functional study showed NK cells expressing KIR3DS1 more potently inhibited HIV replication in target cells expressing HLA-B Bw4-80I compared with KIR3DS1 negative cells [21]. Surprisingly, in the first cohort, the combination of KIR3DL1*h/y + HLA-B Bw4-80I was also shown to be protective against HIV progression [22]. All of these studies suggest that NK cells expressing KIR molecules that interact with their HLA ligands might play an important role in the outcome of HIV-1 infection.

In this study we have examined the relationship between KIR polymorphism and clinical outcome in a unique village cohort of HIV-1-infected former plasma donors (FPDs) in Henan...
province, China. The cohort was established in a single village in 2004, when most of the individuals had been living with HIV-1 for more than 10 years without anti-retroviral therapy (ART), and could therefore be regarded as “slow progressors”. This cohort provides particular advantages for genetic association studies because most of the major factors that are known to affect the natural history of HIV-1 infection, such as viral strain, transmission route and timing of infection, were very similar amongst all participants, as previously described [23]. Although no samples were available from rapid progressors who died from HIV-1 complications prior to 2004, we compared HLA and KIR frequencies in the HIV-1 cohort with those in a nearby village which did not participate in the plasma donation scheme. Our hypothesis was that if specific KIR genes or KIR-HLA combinations provide protection against HIV-1 progression, they may have become enriched in these “slow progressors” compared to the general population.

Materials and methods
Study populations
SM village is an isolated rural community in Henan province in central China. Between 1994 and 1995, many villagers in this community participated in a paid plasma donation scheme which became contaminated with HIV-1, thought to be due either to contamination of blood collection equipment or pooled red cells being returned to donors [24]. The SM cohort was established in 2004, when most of the HIV-infected former plasma donors (FPD) had survived with HIV for more than 10 years in the absence of ART. 149 premature deaths had been recorded in the village with symptoms compatible with HIV-1 disease before 2004. To a certain extent all of the 261 individuals in the SM cohort can be regarded as “slow progressors” [25–27]. Phylogenetic analysis of the infecting virus, studying the p17 region of gag and C2-V3 regions of env, suggested that the paid plasma donation associated HIV-1 subtype B epidemic in central China is monophyletic [28]. Based on the epidemiological history and further phylogenetic analysis of the HIV-1 Gag, Pol, and Nef proviral sequences in the SM FPDs, the SM village outbreak was also considered to be a narrow-source infection [23]. In order to compensate for the loss of “rapid progressors” from the cohort, 252 healthy Han Chinese donors were recruited from a nearby village that had not taken part in the illegal plasma donation scheme to provide population HLA and KIR frequencies.

This study was approved by the Ethics committees of Beijing You’an hospital and Oxford University (OxTREC). All the participants provided their written informed consent with the assistance of medical staff prior to sample collection.

DNA isolation
Genomic DNA was extracted from 300μl of whole blood containing EDTA, using a DNA isolation kit according to the manufacturer’s instructions, and quantified by Nanodrop spectrometry.

KIR and HLA class I genotyping
Genomic DNA was genotyped using a polymerase chain reaction-sequence specific priming (PCR-SSP) technique to detect the presence or absence of the following inhibitory genes: KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3; activating genes: KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, and pseudogene KIR2DP1 as previously described [29]. HLA class I genotyping was performed using sequence-based techniques. Briefly, locus-specific primers flanking exons 2 and 3 were used to amplify each locus and two other pairs of internal primers were used to sequence the purified PCR.
products in both directions with a BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems, Foster city, CA).

**Statistical analysis**

Stata version 14.1 (StataCorp, Texas, USA) was used to perform all statistical analyses. Frequencies of genes, alleles, genotypes and haplotypes were determined using direct counting. Heterogeneity in frequencies of genes, alleles, genotypes and haplotypes between HIV-infected and HIV-uninfected groups was determined using Chi-squared or Fisher’s exact tests as may be appropriate. P-values of <0.05 after Bonferroni correction for multiple testing were considered significant.

**Results**

**Demographic and clinical characteristics of participants**

Blood samples were collected from all 261 identified former plasma donors in the SM village with chronic HIV-1 infection. Demographic and clinical characteristics are available for 258 treatment naïve adults with mean age of 43 years, 56% of whom were females (Table 1).

Two hundred and thirty-eight HIV-1 infected participants had baseline CD4 count data and 93 had viral load measured at recruitment with 29% being undetectable. The mean duration of infection without any form of anti-retroviral therapy was 14.6 years with a substantial number (34%) still relatively healthy with CD4 counts above 500 cells/mL.

**KIR gene frequencies in the Han Chinese cohorts**

We report the frequencies of 15 KIR genes in a unique cohort of HIV-1 infected and uninfected Henan Han Chinese population. We observed that all three frame work genes

| Gender | Total number (n = 258) | Mean±SD (%) |
|--------|------------------------|-------------|
| Male   | 113                    | 43.80%      |
| Female | 145                    | 56.20%      |

| Age (years) | Total number | Mean±SD (27–60) |
|-------------|--------------|-----------------|
| 258         | 42.98 ± 9.84 |

| Duration of Infection (years) | Total number | Mean±SD (12–16) |
|------------------------------|--------------|-----------------|
| 258                          | 14.56 ± 1.42 |

| Route of infection / therapy | Total number (n = 258) | %     |
|------------------------------|------------------------|-------|
| Plasma donation              | 258                    | 100%  |
| Other                        | 0                      | 0     |
| ART before 2004              | 0                      | 100%  |
| ART after 2004               | 121                    | 46.90%|

| Viral load† / CD4 counts†     | Total number | %     |
|------------------------------|--------------|-------|
| VL < 50                      | 27           | 29.03%|
| VL ≤ 2000 (≤3.3log)          | 8            | 8.60% |
| VL > 2000 (>3.3log)          | 58           | 62.37%|
| CD4 ≥ 500                    | 81           | 34.03%|
| 200 ≥ CD4 < 500              | 87           | 36.56%|
| CD4 < 200                    | 70           | 29.41%|

*: Viral loads were measured and reported as copies per mL of blood collected from 93 participants
†: CD4+ T cell counts were performed and reported as number of CD4+ T cells per mL of blood, 238 participants had baseline CD4 data.

https://doi.org/10.1371/journal.pone.0195452.t001
investigated namely KIR2DL4, KIR3DL2 and KIR3DL3, were present in all 252 control (uninfected) participants and in nearly all (>99.2%) HIV-1 infected individuals. Other genes present at high frequencies (>97%) in the uninfected group included two inhibitory genes (KIR2DL1 and KIR2DL3), one activating gene (KIR2DS4), and the pseudogene (KIR2DP1). In addition to the aforementioned genes, KIR3DL1 frequency was high in the HIV-1 infected group (Table 2).

In general most activating KIRs (except KIR2DS4) were significantly less frequent compared to their inhibitory counterparts with the least frequent being KIR2DS3 (13.8% and 17.9% in cases and controls, respectively).

KIR2DL3 associates with non-protection against rapid disease progression

Comparative analysis of individual KIR genes between cases and controls revealed that the inhibitory gene KIR2DL3 was significantly overrepresented in the uninfected group (99.2% vs. 95.8% in control and cases, respectively, corrected P-values = 0.021). Given that the HIV+ group (n = 261) is enriched with long-term non-progressors and slow progressors, this finding may suggest that a disproportionate number of KIR2DL3+ individuals who participated in the blood donation scheme in the SM village may have died prior to 2004 when this cohort was established. It may be worth mentioning here that KIR2DL3 is part of a dimorphic group (KIR2DL2/L3) with both genes occupying the same locus on human chromosome 19. We did not see this effect with KIR2DL2 which was equally distributed between groups (S1 Table). The underrepresentation of KIR2DL3 among HIV-1 survivors (slow progressors) and its plausible association with HIV disease progression is independent of its dimorphic nature.

KIR gene frequencies are similar between Henan Chinese Han and other Han populations

Here, we compared KIR frequencies in the uninfected Henan Chinese Han that participated in the present study (n = 252) to those of other Chinese Han populations including Zhejiang.

Table 2. KIR frequency distribution between SM patients and healthy controls.

| KIR gene   | SM patients % | Healthy control % | P     |
|------------|---------------|-------------------|-------|
|            | n = 261       |                   |       |
| KIR2DL1    | 98.5          | 100               | 0.124 F |
| KIR2DL2    | 22.6          | 21.8              | 0.915 |
| KIR2DL3    | 95.8          | 99.2              | 0.021 |
| KIR2DL4    | 99.2          | 100               | 0.499 F |
| KIR2DL5    | 39.5          | 42.9              | 0.435 |
| KIR2DS1    | 34.9          | 37.3              | 0.566 |
| KIR2DS2    | 21.5          | 20.6              | 0.820 |
| KIR2DS3    | 13.8          | 17.9              | 0.207 |
| KIR2DS4    | 98.1          | 97.2              | 0.571 F |
| KIR2DS5    | 28.7          | 29.4              | 0.875 |
| KIR3DL1    | 97.3          | 94.1              | 0.068 |
| KIR3DL2    | 100           | 100               | -     |
| KIR3DL3    | 100           | 100               | -     |
| KIR3DS1    | 31            | 38.1              | 0.096 |
| KIR2DP1    | 98.5          | 100               | 0.124 F |

Pearson Chi-Square was used to perform the comparison.
*: Fisher’s Exact Test. P<0.05 was significant.
- represents no comparison.

https://doi.org/10.1371/journal.pone.0195452.t002
Chinese Han [30] and Jiangshu Chinese Han [31]. Our observed KIR frequencies were also compared against those reported by Miyashita and colleagues in a Japanese population [32] (S1 Fig). With the exception of KIR2DL5 and KIR2DS4, only marginal differences were observed between the three Chinese Han populations and Japanese. The frequency of KIR2DL5 is highly variable between populations: lower in Zhejiang Chinese Han (30.8%) and higher in the Japanese (48.5%). This difference, however, disappeared after correction for multiplicity testing by the Bonferroni’s method. A highly significant difference was seen with KIR2DS4, which was significantly less frequent in the Japanese population (87%) compared to Chinese Han (S1 Fig). There was also some variability in the frequency of KIR2DS4 amongst Chinese Han populations. Whereas every Chinese Han in Zhejiang has KIR2DS4, 7.3% of Jiangshu Chinese Han individuals lack this activating gene.

**KIR genotype/haplotype distribution and association with disease**

Using the number of KIR genes present in each participant, we computed individual KIR genotypes and compared with existing data in public databases such as the “Allele frequency.net” [33]. In the present study, 54 genotypes were identified in 513 individuals. S1 Table shows the frequencies of most frequent genotypes (present in at least 1% of the study population). Genotype 1 is the most common genotype worldwide and was present in 50% of our samples.

**HLA class I gene frequencies in HIV-1-infected and uninfected groups**

We generated HLA class I data on 233 cases and 252 controls. Table 3 shows the distribution of HLA class I genotypes detected in our study population.

| HLA class I HLA-A alleles | SM patients(n = 233) % | Healthy controls(n = 252) % | P |
|---------------------------|------------------------|-----------------------------|---|
| A’01                      | 10.3                   | 6.8                         | 0.164 |
| A’02                      | 53.2                   | 47.8                        | 0.235 |
| A’03                      | 8.2                    | 6.8                         | 0.563 |
| A’11                      | 24.5                   | 26.3                        | 0.644 |
| A’24                      | 24.5                   | 29.9                        | 0.182 |
| A’26                      | 2.6                    | 6.4                         | 0.045 |
| A’31                      | 5.6                    | 6.4                         | 0.713 |
| A’32                      | 6.4                    | 4.8                         | 0.428 |
| A’33                      | 21.0                   | 24.7                        | 0.338 |
| HLA-B alleles             |                        |                             |     |
| B’07                      | 7.7                    | 9.2                         | 0.571 |
| B’08                      | 2.6                    | 2.0                         | 0.668 |
| B’13                      | 21.0                   | 26.3                        | 0.174 |
| B’15                      | 17.6                   | 20.3                        | 0.446 |
| B’27                      | 7.3                    | 4.0                         | 0.113 |
| B’35                      | 6.9                    | 5.6                         | 0.557 |
| B’37                      | 3.9                    | 2.8                         | 0.510 |
| B’38                      | 5.6                    | 6.8                         | 0.587 |
| B’39                      | 3.9                    | 4.0                         | 0.945 |
| B’40                      | 29.2                   | 25.5                        | 0.363 |
| B’44                      | 13.7                   | 17.5                        | 0.252 |
| B’46                      | 9.4                    | 10.0                        | 0.848 |

(Continued)
At the group specific levels (2-digit HLA data), we found 9 HLA-A (01, 02, 03, 11, 24, 26, 31, 32, and 33) with HLA-A*02 being the most common in both groups. HLA-A*26 tended to be slightly overrepresented in the uninfected control group compared to cases (6.4% vs. 2.6%, respectively). Similarly, 19 different HLA-B groups of alleles were present in our study population, albeit with a similar distribution between cases and controls, and HLA-B*40 and HLA-B*13 were the most common. Among the 10 HLA-C group of alleles that were detected in this study, HLA-Cw*03 was the most frequent (39.0% and 33.6% in controls and cases respectively). However, HLA-Cw*02 was marginally overrepresented in cases compared to controls (Table 3).

Centromeric and telomeric KIR motifs and genotypes in HIV-1-infected and uninfected groups

We adopted the recent techniques and terminologies used by Cooley et al [34] and Pyo et al [35] to assign centromeric (cen) and telomeric (tel) motifs and genotypes to each study sample. Comparisons of the group of genes present at the telomeric and centromeric parts of the KIR gene loci were performed between the two groups. The frequencies of most telomeric and centromeric motifs as well as genotypes were very similar between the SM patient group and the healthy control group (Table 4). However, a significant difference was observed amongst people carrying the telomeric genotype B1/Bx (with Bx representing other Tel-B genotypes), which was significantly less frequent in the SM patient group (0.4%) compared to the healthy control group (2.8%).

Compound KIR-HLA genotype comparison between HIV-1-infected and uninfected groups

Using known KIR-HLA ligand-receptor relationships, we computed compound genotypes for each study participant and compared their frequencies between groups. We found that the compound genotype KIR3DS1 + HLA-Bw4 was relatively less frequent in the SM patient group (6%) than in the healthy control group (12%) (Table 5).

Table 3. (Continued)

| HLA class I | SM patients(n = 233) % | Healthy controls(n = 252) % | P     |
|-------------|------------------------|-----------------------------|-------|
| HLA-A       |                        |                             |       |
| A*01        | 5.6                    | 4.4                         | 0.545 |
| A*02        | 14.2                   | 16.7                        | 0.436 |
| A*03        | 8.2                    | 7.2                         | 0.685 |
| A*04        | 6.4                    | 5.2                         | 0.554 |
| A*05        | 2.2                    | 3.6                         | 0.346 |
| A*07        | 4.7                    | 3.2                         | 0.386 |
| A*08        | 11.6                   | 11.6                        | 0.991 |
| HLA-B       |                        |                             |       |
| B*40        | 18.6                   | 18.3                        | 0.942 |
| B*51        | 5.8                    | 2.0                         | 0.032 |
| B*52        | 33.6                   | 39                          | 0.22  |
| B*54        | 9.7                    | 10.8                        | 0.714 |
| B*55        | 29.7                   | 27.9                        | 0.672 |
| B*57        | 28.8                   | 29.1                        | 0.938 |
| B*58        | 22.6                   | 16.3                        | 0.085 |
| B*59        | 11.1                   | 9.2                         | 0.492 |
| B*60        | 10.6                   | 13.9                        | 0.271 |
| B*61        | 11.1                   | 13.9                        | 0.344 |

https://doi.org/10.1371/journal.pone.0195452.t003
Discussion

HIV-1 infection represents a complex interaction between a polymorphic virus and a polymorphic host immune system over many years of infection. In the attempt to understand why HIV-1 outcomes can differ so markedly between individuals, immunogenetic studies provide an in vivo population view of factors that affect the host response to the virus, providing suggestions for subsequent in vitro functional studies.

There have been few previous studies of the immunogenetic associations of HIV-1 infection in Chinese people. The SM cohort presents several unique advantages for genetic studies: firstly, almost all the individuals in the SM patient group were infected during a very short period of time, between 1993 and 1995 when the paid plasma donation scheme was prevalent in rural areas of Henan province; secondly, based on the analysis of the infecting HIV-1 sequences [23], the cohort as a whole was infected by a relatively narrow source virus and occurred only in individuals with an evident plasma donation history, which strongly suggests that they were infected via the same blood contamination route. Hence, one side of the virus-

Table 4. Centromeric and telomeric motif and genotype distribution in the study population.

|                        | SM patients (%) | Healthy controls (%) | P   |
|------------------------|-----------------|----------------------|-----|
| **Centromeric motifs** |                 |                      |     |
| cen-A                  | 72.8            | 75.8                 | 0.438 |
| cen-B1                 | 6.5             | 3.6                  | 0.129 |
| cen-B2                 | 14.2            | 16.7                 | 0.435 |
| cen-B3                 | 23              | 23.4                 | 0.909 |
| cen-Bx                 | 6.1             | 4.4                  | 0.371 |
| **Telomeric motifs**   |                 |                      |     |
| tel-A                  | 96.9            | 94.1                 | 0.115 |
| tel-B1                 | 25.3            | 32.9                 | 0.570 |
| tel-Bx                 | 16.1            | 12.7                 | 0.275 |
| **Centromeric genotype** |               |                      |     |
| c-A/A                  | 52.5            | 52.4                 | 0.980 |
| c-A/B1                 | 4.6             | 3.6                  | 0.558 |
| c-A/B2                 | 13              | 16.7                 | 0.246 |
| c-A/Bx                 | 2.7             | 3.2                  | 0.741 |
| c-B1/B1                | 0.4             | 0                    | 1.000 |
| c-B1/Bx                | 1.5             | 0                    | 0.124 |
| c-B2/B2                | 1.2             | 0                    | 0.249 |
| c-B3/B3                | 22.2            | 23                   | 0.830 |
| c-B3/Bx                | 0.8             | 0.4                  | 1.000 |
| c-Bx/Bx                | 1.2             | 0.8                  | 1.000 |
| **Telomeric genotype** |                 |                      |     |
| t-A/A                  | 59              | 57.1                 | 0.670 |
| t-A/B1                 | 23              | 27.4                 | 0.252 |
| t-A/Bx                 | 14.9            | 9.5                  | 0.062 |
| t-B1/B1                | 1.9             | 2.8                  | 0.519 |
| t-B1/Bx                | 0.4             | 2.8                  | 0.035 |
| t-Bx/Bx                | 0.8             | 0.4                  | 1.000 |

Cen: centromeric; Tel: telomeric; Cen-Bx: other Cen-B genotypes except Cen-B1, Cen-B2 and Cen-B3. Tel-Bx: other Tel-B genotypes except Tel-B1.

https://doi.org/10.1371/journal.pone.0195452.t004
host dynamic is relatively constant, which provides a unique advantage to evaluate how the other side, host factors, will shape the outcome of HIV-1 infection. Previous studies in the same cohort showed that CTL pressure has a major effect on inter-host HIV-1 viral diversity and is therefore thought to represent a key element of viral control [23]; however, CTL pressure alone accounted for only around 50% of the observed viral variant, implicating the involvement of additional components of the immune system in HIV-1 control. Moreover, HLA class I molecules, as the central part of the CTL immune response, are also the major KIR ligands, which highlights the potential role for KIRs in defence against HIV-1 infection.

One of the unavoidable problems encountered in this analysis, which is often seen in this kind of retrospective study, is that the ‘rapid progressors’ at one end of the progression spectrum have already died and are, therefore, missing due to frailty bias, which may limit the power of comparison. Although we acknowledge the limitations, recruitment of healthy controls from a geographically adjacent village have to some extent compensated for this lack of power. On the other hand, it is appreciated that this healthy control group was not recruited with the specific aim of studying susceptibility to HIV-1 infection.

Our first analysis described the profile of KIR gene distribution in the two groups of Chinese Han. No significant differences were seen for most of the KIR genes between the groups, except for KIR2DL3. KIR2DL3 was previously shown to be associated with an increased likelihood of viral clearance following acute hepatitis C viral infection [36]. The presumed mechanism underlying this observation is that the weaker inhibitory interaction of KIR2DL3 with C1, but not the stronger inhibitory interaction of KIR2DL2 and KIR2DL1 with C1 and C2, could allow penetrance of activating signals during viral infection. In our study, a significant difference of KIR2DL3 frequency was also detected between the “slow progressors” and the healthy controls. Since it is necessary to incorporate the KIR ligand interactions into a biological model rather than considering KIRs in isolation, we further investigated KIR2DL3+C1C1 or C1C2 between the two groups, but no further significant differences were found. Hence the initial difference has to be considered with caution. In the healthy controls, the frequency of KIR2DL3 was 99.2%, which was similar to that reported in other two Chinese Han

| KIR-HLA*       | SM patients group (%) | Healthy control group (%) | P     |
|---------------|-----------------------|---------------------------|-------|
| 3DS1+Bw4/x    | 25.3                  | 29.9                      | 0.263 |
| 3DL1+Bw4/x    | 73.0                  | 71.3                      | 0.687 |
| 3DL1S1+Bw4/x  | 74.3                  | 75.7                      | 0.713 |
| 3DS1+Bw4/Bw4  | 6.0                   | 12.0                      | 0.023 |
| 3DL1+Bw4/Bw4  | 22.3                  | 22.0                      | 0.831 |
| 3DL1S1+Bw4/Bw4| 22.3                  | 23.9                      | 0.680 |
| 2DL2+C1/x     | 20.4                  | 19.9                      | 0.906 |
| 2DL3+C1/x     | 86.7                  | 90.0                      | 0.258 |
| 2DL2/3+C1/x   | 90.3                  | 90.0                      | 0.934 |
| 2DS2+C1/x     | 19.5                  | 18.7                      | 0.837 |
| 2DL2+C1/C1    | 10.2                  | 10.0                      | 0.937 |
| 2DL3+C1/C1    | 46.5                  | 48.6                      | 0.640 |
| 2DS2+C1/C1    | 9.3                   | 9.6                       | 0.920 |
| 2DL1+C2/x     | 50.0                  | 51.0                      | 0.828 |
| 2DS1+C2/x     | 22.6                  | 19.1                      | 0.355 |

*: x represents Bw4, Bw6, C1, or C2

https://doi.org/10.1371/journal.pone.0195452.t005
populations, at 99% and 100%, respectively [30,31]: however, in the SM patient group the frequency of KIR2DL3 (95.8%) was significantly lower. The KIR gene frequencies were generated using SSP-PCR typing, which relies on sequence-specific primers to amplify specific KIR genes. It is plausible that variation in the binding positions of these "sequence-specific" primers could lead to a reported absence of the gene if rare alleles of KIR2DL3 were present, although it would be surprising for this only to occur in the HIV-1-infected cohort.

The predominant variation between KIR genotypes is in the number of genes, leading to distinct A and B haplotypes [37]. The A haplotype can be identified by the presence of KIR2DS4 as the only activating receptor gene, whereas B haplotypes express multiple activating receptors, but not KIR2DS4 [38]. In general, A haplotypes have been associated with an improved response to pathogens, whereas B haplotypes are linked with improved reproductive fitness [39–41]. In our study, the A haplotype (genotype 1 in S1 Table) accounted for 50% of SM patients, at a similar frequency to that (51%) in healthy controls.

The KIR3DL1/S1 gene is distinct due to its diversity and varied expression patterns. It is the only KIR locus that encodes both inhibitory and activating allotypes. KIR3DL1 recognises HLA-B and HLA-A alleles that express the Bw4 serological motif. Although KIR3DL1 and KIR3DS1 share high similarity and Bw4 has been proposed to be the ligand for KIR3DS1, no direct binding of KIR3DS1 and Bw4 has yet been demonstrated. However, several epidemiological and functional studies support some kind of interaction between KIR3DS1 and HLA-B Bw4-80I in the NK cell response to HIV infection. Martin and colleagues reported that KIR3DS1+HLA B Bw4-80I was protective against HIV progression [13], but this has not been found in other studies: indeed, Gaudieri et al reported that individuals with KIR3DS1 and Bw4-80I actually exhibited an accelerated progression to AIDS [11] whilst O’Connell et al noted there was no correlation between KIR/HLA genotype and control of HIV replication by NK cells in vitro in a small cohort of elite controllers [42]. In our study, the frequency of KIR3DS1+ Bw4 homozygotes was significantly lower in the SM “slow progressors” group (6%) compared to that (12%) in the healthy group. This observation implies that there has been a loss of this compound genotype in the “slow progressors”, which could either imply that this combination does not mediate delayed HIV progression, or alternatively, that the presence of this compound genotype protects against blood-borne HIV-1 infection. In our study, we were unable to assign each Bw4 motif to 80I or 80T subgroups, so could not investigate the effect of KIR3DS1+Bw4-80I in this cohort.

KIR3DL1 shows extensive polymorphism, and its variation has functional significance in terms of cell surface expression levels and inhibitory capacity, which was shown to be relevant in a previous association study with HIV infection [22]. However in our study there was no correlation with KIR3DL1/Bw4 genotype and HIV progression.

Additional confounders of this study might include limitations in the sample sizes used for the two cohorts. Despite the relatively small sample sizes, the “genetic association effect” could potentially be magnified because other confounders such as ethnicity, infecting founder viruses, transmission routes and infection durations are largely controlled for in the SM cohort.

It is becoming apparent that host genetic variation can exert significant selective pressure on the virus [43]. The advantage of genetic epidemiological studies is that they can provide an in vivo population view of factors that affect the host response differentially across humans, giving meaning to subsequent functional studies to further investigate the molecular basis of their impact on AIDS pathogenesis and help clarify the relative contribution of the innate and adaptive immune response, which may lead in turn to the development of better therapies and vaccines.
Supporting information

S1 Fig. KIR gene frequencies in Henan Chinese Han and neighbouring populations. Zhejiang Chinese Han [30], Jiangshu Chinese Han [31], and Japanese [32]. **: P = 5.3x10^{-6} (DOCX)

S1 Table. KIR genotype distribution in the SM cohort. *: Genotype identification numbers are unique numbers assigned as per available data in AlleleFrequency in worldwide population database. (XLS)

Acknowledgments

LW, YZ, KX, TD, SRJ, and LM contributed to the design and implementation of the study, wrote and edited the manuscripts; LW, YZ, and LM performed the experiments; LW, YZ and LM analysed the data.

This work was supported by the Medical Research Council UK, the Li Ka Shing Foundation, the National Key Clinical Department of Infectious Diseases, the Beijing High-Level Healthcare Intelligent Culture Plan (2015-3-109), the National Natural Science Foundation of China (81320108017), the Beijing municipal administration of hospitals (XMLX201411 and ZYX201711), the Beijing Municipal Science & Technology Commission (Z17110001017078), and the Beijing Key Laboratory (BZ0373). We are very grateful to all participants in this study. We also thank all the clinical staff who made major contributions to establishing the SM cohort and collecting all the samples.

Author Contributions

Conceptualization: Linghang Wang, Yonghong Zhang, Keyi Xu, Tao Dong, Sarah Rowland-Jones, Louis-Marie Yindom.

Data curation: Linghang Wang, Louis-Marie Yindom.

Formal analysis: Linghang Wang, Yonghong Zhang, Tao Dong, Louis-Marie Yindom.

Funding acquisition: Keyi Xu, Tao Dong, Sarah Rowland-Jones.

Investigation: Linghang Wang, Yonghong Zhang, Louis-Marie Yindom.

Methodology: Linghang Wang, Yonghong Zhang, Louis-Marie Yindom.

Project administration: Keyi Xu, Tao Dong, Sarah Rowland-Jones, Louis-Marie Yindom.

Resources: Sarah Rowland-Jones, Louis-Marie Yindom.

Software: Louis-Marie Yindom.

Supervision: Keyi Xu, Tao Dong, Sarah Rowland-Jones, Louis-Marie Yindom.

Validation: Louis-Marie Yindom.

Writing – original draft: Linghang Wang, Yonghong Zhang, Tao Dong, Sarah Rowland-Jones, Louis-Marie Yindom.

Writing – review & editing: Linghang Wang, Yonghong Zhang, Keyi Xu, Tao Dong, Sarah Rowland-Jones, Louis-Marie Yindom.

References

1. Lanier LL (1998) NK cell receptors. Annu Rev Immunol 16: 359–393. https://doi.org/10.1146/annurev.immunol.16.1.359 PMID: 9597134
2. Trowsdale J (2001) Genetic and Functional Relationships between MHC and NK Receptor Genes. Immunity 15: 363–374. PMID: 11567627

3. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, et al. (2002) Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 168: 2307–2315. PMID: 11859120

4. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P (2008) MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112: 2369–2380. https://doi.org/10.1182/blood-2008-03-143727 PMID: 18583565

5. Parham P (2008) The genetic and evolutionary balances in human NK cell receptor diversity. Semin Immunol 20: 311–316. https://doi.org/10.1016/j.smim.2008.10.002 PMID: 19036608

6. Gendzekhadze K, Norman PJ, Abi-Rached L, Layrisse Z, Parham P (2006) High KIR diversity in Amerindians is maintained using few gene-content haplotypes. Immunogenetics 58: 474–480. https://doi.org/10.1007/s00251-006-0108-3 PMID: 16738943

7. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, et al. (2000) Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A 97: 4778–4783. https://doi.org/10.1073/pnas.001073397 PMID: 110781084

8. Qi Y, Martin MP, Gao X, Jacobson L, Detels R, Goedert JJ, et al. (2006) KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC infectious diseases 13: 405. https://doi.org/10.1186/1471-2334-13-405 PMID: 20459286

9. Carrington M, Martin MP, van Bergen J (2008) KIR-HLA intercourse in HIV disease. Trends Microbiol 16: 620–627. https://doi.org/10.1016/j.tim.2008.09.002 PMID: 18976921

10. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, et al. (2001) Conformer of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat Immunol 2: 413–418. https://doi.org/10.1038/ni.3513 PMID: 11567627

11. Barbour JD, Sriram U, Caillier SJ, Levy JA, Lanier LL (2007) Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 178: 647–651. PMID: 17202323

12. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schniedewind A, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204: 3027–3036. https://doi.org/10.1084/jem.20070695 PMID: 18025129
22. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39: 733–740. https://doi.org/10.1038/ng2035 PMID: 17496894
23. Dong T, Zhang Y, Xu KY, Yan H, James I, Peng Y, et al. (2011) Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China. Blood 118: 98–106. https://doi.org/10.1182/blood-2010-06-291983 PMID: 21562042
24. Kaufman J, Jing J (2002) China and AIDS—the time to act is now. Science 296: 2339–2340. https://doi.org/10.1126/science.1074479 PMID: 12089428
25. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P, et al. (2011) Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1**+/** and HLA-B*57. J Virol 85: 5949–5960. https://doi.org/10.1128/JVI.02652-10 PMID: 21471235
26. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, et al. (2002) Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS 16: 961–972. PMID: 11953462
27. Zhang Z, Jiang Y, Zhang M, Liu J, Sun G, Shi W, et al. (2010) Alterations of CD4(+) CD25(+) Foxp3(+) regulatory T cells in HIV-infected slow progressors of former blood donors in China. Microbiology and Immunology 54: 625–633. https://doi.org/10.1111/j.1348-0421.2010.00529.x PMID: 21183000
28. Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, et al. (2004) Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78: 13591–13599. https://doi.org/10.1128/JVI.78.24.13591-13599.2004 PMID: 15664470
29. Martin MP, Carrington M (2008) KIR locus polymorphisms: genotyping and disease association analysis. Methods Mol Biol 415: 49–64. https://doi.org/10.1007/978-1-59745-570-1_3 PMID: 18370147
30. Jiang K, Zhu FM, Lv QF, Yan LX (2005) Distribution of killer cell immunoglobulin-like receptor genes in the Chinese Han population. Tissue Antigens 65: 556–563. https://doi.org/10.1111/j.1399-0039.2005.00412.x PMID: 15896204
31. Bao X, Hou L, Sun A, Qiu Q, Yuan X, Chen M, et al. (2010) Distribution of killer cell immunoglobulin-like receptor genes and 2DS4 alleles in the Chinese Han population. Hum Immunol 71: 289–292. https://doi.org/10.1016/j.ki.2009.12.004 PMID: 20034528
32. Miyashita R, Tsuchiya N, Yabe T, Kobayashi S, Hashimoto H, Ozaki S, et al. (2006) Association of killer cell immunoglobulin-like receptor genotypes with microscopic polyangiitis. Arthritis and Rheumatism 54: 992–997. https://doi.org/10.1002/art.21653 PMID: 16508981
33. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. (2015) Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 43: D784–788. https://doi.org/10.1093/nar/gku1166 PMID: 25414323
34. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116: 2411–2419. https://doi.org/10.1182/blood-2010-05-283051 PMID: 20581313
35. Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ, et al. (2010) Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus PLoS One 5: e15115. https://doi.org/10.1371/journal.pone.0015115 PMID: 21206914
36. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872–874. https://doi.org/10.1126/science.1097670 PMID: 15297676
37. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, et al. (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753–763. PMID: 9430221
38. Vilches C, Pando MJ, Parham P (2000) Genes encoding human killer-cell Ig-like receptors with D1 and D2 extracellular domains all contain untranslated pseudogenes encoding a third Ig-like domain. Immunogenetics 51: 639–646. PMID: 10941835
39. Lu Z, Zhang B, Chen S, Gai Z, Feng Z, Liu X, et al. (2008) Association of KIR genotypes and haplotypes with susceptibility to chronic hepatitis B virus infection in Chinese han population. Cellular and Molecular Immunology 5: 457–463. https://doi.org/10.1038/cmi.2008.57 PMID: 19118512
40. Cheent K, Khakoo SI (2009) Natural killer cells: integrating diversity with function. Immunology 126: 449–457. https://doi.org/10.1111/j.1365-2567.2009.03045.x PMID: 19278418
41. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, et al. (2010) Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 120: 4102–4110. https://doi.org/10.1172/JCI43998 PMID: 20972337
42. O’Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN (2009) Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 83: 5028–5034. https://doi.org/10.1128/JVI.02551-08 PMID: 19211742

43. Martin MP, Carrington M (2013) Immunogenetics of HIV disease. Immunol Rev 254: 245–264. https://doi.org/10.1111/imr.12071 PMID: 23772624